Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1G93A mouse model of amyotrophic lateral sclerosis

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Lee, Jia Y ^a   Lee, John D ^a   Phipps, Simon ^a   Noakes, Peter G ^a   Woodruff, Trent M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

HMGB1; Motor neuron disease; Neuro inflammation; TLR4

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; TOLL LIKE RECEPTOR 4; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; CHOLINE ACETYLTRANSFERASE; GLIAL FIBRILLARY ACIDIC PROTEIN; MESSENGER RNA; SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE; TOLL LIKE RECEPTOR 3;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GRIP STRENGTH TEST; HINDLIMB; IMMUNOHISTOCHEMISTRY; LUMBAR SPINAL CORD; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SURVIVAL; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MORTALITY; MUSCLE STRENGTH; PATHOLOGY; PATHOPHYSIOLOGY; SPINAL CORD; SURVIVAL ANALYSIS; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BODY WEIGHT; CALCIUM-BINDING PROTEINS; CHOLINE O-ACETYLTRANSFERASE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HINDLIMB; HMGB1 PROTEIN; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; MUSCLE STRENGTH; RNA, MESSENGER; SPINAL CORD; SUPEROXIDE DISMUTASE; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 3;

EID: 85019201729     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-015-0310-z     Document Type: Article

References (20)

1. Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004;27:723-49.
2. Cozzolino M, Ferri A, Carri MT. Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications. Antioxid Redox Signal. 2008;10:405-43.
3. Evans MC, Couch Y, Sibson N, Turner MR. Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci. 2013;53:34-41.
4. McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve. 2002;26:459-70.
5. Mantovani S, Gordon R, Macmaw JK, Pfluger CM, Henderson RD, Noakes PG, et al. Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood. J Neuroimmunol. 2014;276:213-8.
6. Jou I, Lee JH, Park SY, Yoon HJ, Joe EH, Park EJ. Gangliosides trigger inflammatory responses via TLR4 in brain glia. Am J Pathol. 2006;168:1619-30.
7. Tang SC, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG, et al. Pivotal role for neuronal toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A. 2007;104:13798-803.
8. De Paola M, Mariani A, Bigini P, Peviani M, Ferrara G, Molteni M, et al. Neuroprotective effects of toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration. Mol Med. 2012;18:971-81.
9. Elliott JL. Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res Mol Brain Res. 2001;95:172-8.
10. Letiembre M, Liu Y, Walter S, Hao W, Pfander T, Wrede A, et al. Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol Aging. 2009;30:759-68.
11. Casula M, Iyer AM, Spliet WG, Anink JJ, Steentjes K, Sta M, et al. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience. 2011;179:233-43.
12. Lee JD, Kamaruzaman NA, Fung JN, Taylor SM, Turner BJ, Atkin JD, et al. Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2013;10:119.
13. Ludolph AC, Bendotti C, Blaugrund E, Hengerer B, Loffler JP, Martin J, et al. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. Amyotroph Lateral Scler. 2007;8:217-23.
14. Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler. 2008;9:4-15.
15. WoodruffTM, Lee JD, Noakes PG. Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. Proc Natl Acad Sci U S A. 2014;111:E3-4.
16. Lee JD, Lee JY, Taylor SM, Noakes PG, WoodruffTM. Innate Immunity in ALS. In Amyotrophic Lateral Sclerosis. Edited by (Ed.) PMM: InTech; 2012
17. Yamamoto M, Takeda K. Current views of toll-like receptor signaling pathways. Gastroenterol Res Pract. 2010;2010:240365.
18. Hua F, Ma J, Ha T, Xia Y, Kelley J, Williams DL, et al. Activation of toll-like receptor 4 signaling contributes to hippocampal neuronal death following global cerebral ischemia/reperfusion. J Neuroimmunol. 2007;190:101-11.
19. Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, et al. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem. 2007;20:947-56.
20. WoodruffTM, Costantini KJ, Crane JW, Atkin JD, Monk PN, Taylor SM, et al. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol. 2008;181:8727-34.